Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval
Bionoid Pharma (OTC:BINP) has received approval from Delaware for its name change to AI Maverick Intel, effective April 30, 2025. The company has initiated the FINRA process to update its name and trading symbol on OTC Markets. This rebranding reflects the company's strategic pivot towards leveraging artificial intelligence for acquiring and growing technology-driven businesses, particularly in AI, biotech, and digital health sectors.
Bionoid Pharma (OTC:BINP) ha ottenuto l'approvazione dal Delaware per il cambio di nome in AI Maverick Intel, con efficacia dal 30 aprile 2025. L'azienda ha avviato la procedura FINRA per aggiornare il nome e il simbolo di negoziazione sui mercati OTC. Questo rebranding riflette la nuova strategia aziendale focalizzata sull'utilizzo dell'intelligenza artificiale per acquisire e sviluppare imprese tecnologiche, in particolare nei settori AI, biotecnologie e salute digitale.
Bionoid Pharma (OTC:BINP) ha recibido la aprobaci贸n de Delaware para cambiar su nombre a AI Maverick Intel, con vigencia a partir del 30 de abril de 2025. La empresa ha iniciado el proceso FINRA para actualizar su nombre y s铆mbolo de cotizaci贸n en los mercados OTC. Este cambio de marca refleja el giro estrat茅gico de la compa帽铆a hacia el aprovechamiento de la inteligencia artificial para adquirir y hacer crecer negocios tecnol贸gicos, especialmente en los sectores de IA, biotecnolog铆a y salud digital.
Bionoid Pharma (OTC:BINP)臧� 2025雲� 4鞗� 30鞚茧秬韯� 須牓鞚� 氚滌儩頃橂姅 AI Maverick Intel搿滌潣 靷獏 氤�瓴届潉 雿鸽澕鞗柎鞐愳劀 鞀轨澑氚涭晿鞀惦媹雼�. 須岇偓電� OTC 鞁滌灔鞐愳劀 鞚措瓿� 瓯半灅 鞁臣鞚� 鞐呺嵃鞚错姼頃橁赴 鞙勴暣 FINRA 鞝堨皑毳� 鞁滌瀾頄堨姷雼堧嫟. 鞚措矆 毽笇霝滊敥鞚� 鞚戈车歆�電レ潉 頇滌毄頃� 旮办垹 欷戩嫭 靷梾, 韸鬼瀳 AI, 靸濍獏瓿淀暀, 霐旍韯� 項姢 攵勳暭鞚� 鞚胳垬 氚� 靹膘灔鞚� 於旍頃橂姅 鞝勲灥鞝� 鞝勴櫂鞚� 氚橃榿頃╇媹雼�.
Bionoid Pharma (OTC:BINP) a obtenu l'approbation du Delaware pour changer son nom en AI Maverick Intel, 脿 compter du 30 avril 2025. La soci茅t茅 a lanc茅 la proc茅dure FINRA afin de mettre 脿 jour son nom et son symbole de cotation sur les march茅s OTC. Ce rebranding refl猫te l'orientation strat茅gique de l'entreprise vers l'exploitation de l'intelligence artificielle pour acqu茅rir et d茅velopper des entreprises technologiques, notamment dans les secteurs de l'IA, des biotechnologies et de la sant茅 num茅rique.
Bionoid Pharma (OTC:BINP) hat die Genehmigung des Bundesstaates Delaware f眉r die Namens盲nderung zu AI Maverick Intel erhalten, die am 30. April 2025 wirksam wird. Das Unternehmen hat den FINRA-Prozess eingeleitet, um seinen Namen und sein Handelssymbol auf den OTC-M盲rkten zu aktualisieren. Dieses Rebranding spiegelt die strategische Neuausrichtung des Unternehmens wider, die darauf abzielt, k眉nstliche Intelligenz zu nutzen, um technologiegetriebene Unternehmen, insbesondere in den Bereichen KI, Biotechnologie und digitale Gesundheit, zu erwerben und zu f枚rdern.
- Strategic repositioning towards high-growth AI and technology sectors
- Potential for new business opportunities in AI, biotech, and digital health
- Significant shift from original pharmaceutical focus may create business uncertainty
- Pending FINRA approval adds regulatory uncertainty to the rebranding process
Company Has Initiated FINRA Process to Complete Rebranding and Ticker Update
NEW YORK CITY, NY / / May 29, 2025 / Bionoid Pharma, Inc. (OTC PINK:BINP) ("Bionoid" or the "Company") is pleased to confirm that, following the previously announced rebranding initiative, the State of Delaware has approved the Company's formal name change to AI Maverick Intel, Inc., effective April 30, 2025. The Company has submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets.
Subject to FINRA's approval, the name and symbol change will be reflected in market listings and all future communications. This step marks the continued execution of the Company's new strategic direction, which centers on leveraging artificial intelligence to acquire, integrate, and grow technology-driven businesses.
"This milestone moves us one step closer to fully implementing the AI Maverick vision," said Wayne Cockburn, CEO. "As we align our public identity with our operational focus, we're unlocking new opportunities to scale our platform and partner with innovators across AI, biotech, and digital health. Our shareholders can expect a bold, tech-forward approach to growth."
About AI Maverick Intel, Inc.
AI Maverick Intel, Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. AI Maverick Intel aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
| | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: AI Maverick Intel, Inc.
View the original on ACCESS Newswire
FAQ
Why is Bionoid Pharma (BINP) changing its name to AI Maverick Intel?
When will BINP stock ticker change after the company name change?
What is the effective date of Bionoid Pharma's name change to AI Maverick Intel?
What sectors will AI Maverick Intel (formerly BINP) focus on?
